ロード中...
Maculopapular Exanthema After the Second Dose of Evolocumab
Evolocumab is a relatively new monoclonal antibody designed to decrease low-density lipoproteins via the inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). It is used alone or in combination with other lipid-lowering agents. Evolocumab was associated with adverse events of skin ras...
保存先:
| 出版年: | Cureus |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Cureus
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8229243/ https://ncbi.nlm.nih.gov/pubmed/34188988 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7759/cureus.15249 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|